Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension

Prehypertension Clinical Trial

— MI-DIET  

Official title:

Examining Factors Influencing Adherence to and Efficacy of a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension: a Series of N-of-1 Interventional Studies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04326686
• Other study ID #: MI-DIET
• Status: Completed
• Phase: N/A
• Start date: October 30, 2020
• Est. completion date: March 25, 2022

Study information

• Verified date: May 2022
• Source: University of Aberdeen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to investigate whether physiological, psychological and environmental factors, at an individual level, modify a) adherence, and b) blood pressure response, to a nuts and wholegrains intervention in participants at risk for developing high blood pressure. For 24 weeks, participants will, on a daily basis, monitor their own blood pressure using a wireless blood pressure monitor and respond to short semi-personalised questionnaires using a wrist-worn device, which also measures activity levels. Participants will receive an intervention of wholegrain foods and nuts to substitute into their diets for 8 weeks, between two 8-week observation periods. The length of the study periods will enable repeated measurements to be taken, in order to assess what factors, on an individual level, are associated with fluctuations in the outcomes. This will provide an insight into the types of factors that can help to explain individual fluctuations in adherence and physiological outcomes, such as blood pressure, that are common in nutrition studies. In the future, this should help in tailoring the way the investigators deliver effective individualised interventions, and enable researchers to be better able to consider and control for factors that can affect adherence and response to dietary interventions.

Description:

The study will be conducted as an interventional N-of-1 study with an A1-B-A2 design of 8 weeks per study period. Prior to the study, participants will be screened and if eligible, will complete a number of baseline questionnaires to provide an overview of their typical eating and lifestyle-related behaviours, and general health. A second visit prior to the start of the study will then be arranged, where participants will undergo a semi-structured interview. Responses from the interview, in combination with their baseline questionnaire responses, will be used to identify factors specific to the participant that show some degree of variability. These will form the basis of the semi-personalised questionnaires delivered via the wrist-worn PRO-Diary device for the duration of the study. During the study, participants will visit the institute in a fasted state every 4 weeks (7 visits total), in order to provide a blood sample for assessment of cholesterol levels and for assessment of biomarkers of wholegrains intake. At the first visit, participants will receive the wireless blood pressure monitor and PRO-Diary wrist device programmed with twice-daily questionnaires at times convenient to the participant. After 2 weeks and every 4 weeks thereafter, participants will be sent a link by email to complete a 24-hour dietary recall. After 8 weeks, participants will begin the intervention phase and receive wholegrains equivalent to 3 portions a day and 1 portion of unsalted nuts per day for the following 8 weeks. Participants will be able to choose from a variety of wholegrain products commonly available at supermarkets. They will also receive dietary advice to follow a Dietary Approaches to Stop Hypertension (DASH) diet aimed at lowering blood pressure. All other measures will continue as previously. At week 16, the wholegrains and nuts will be withdrawn and participants will be followed up for a further 8 weeks. At their final visit to the institute, they will complete the same validated questionnaires as at baseline. Results from the study will be analysed using N-of-1 dynamic modelling to analyse trends over time and determine whether any personalised factors significantly affected adherence to intervention or blood pressure response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: March 25, 2022
• Est. primary completion date: March 25, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Mildly elevated blood pressure levels: systolic blood pressure (SBP) >120 <=140mmHg and/or diastolic blood pressure (DBP) >80 <=90mmHg.

• Low habitual intake of wholegrains: <=7 portions/week

• Body Mass Index (BMI) between 18-35

• Possessing a smartphone capable of running the Qardio app in conjunction with the QardioArm wireless blood pressure monitor

Exclusion Criteria:

• SBP <120 or >140mmHg or DBP <80 or >90mmHg. Participants with SBP > 140 or DBP > 90 will be advised to visit their GP to have their blood pressure reassessed in a clinical setting.

• Diagnosed with diabetes

• Clinically diagnosed with hypertension or hypercholesterolemia

• Unstable or untreated thyroid disorder

• Taking blood pressure- or cholesterol-lowering medications (e.g. beta blockers or statins)

• Following a low carbohydrate/gluten free diet

• Coeliac disease/gluten insensitivity

• Any food allergies

• Being on a weight loss diet or having lost >5kg in the last 6 months

• Any history of an eating disorder

• >7 portions/week habitual wholegrains consumption

• Having taken part in a study where wholegrains were provided in the last 3 months

• Not possessing a smartphone to run the Qardio app.

Related Conditions & MeSH terms

• Prehypertension

Intervention

Other:
• Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet
30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet

Locations

Country	Name	City	State
United Kingdom	The Rowett Institute, University of Aberdeen	Aberdeen	Aberdeen City

Sponsors (3)

Lead Sponsor	Collaborator
University of Aberdeen	Biotechnology and Biological Sciences Research Council, Unilever R&D

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence to wholegrains and nuts consumption	Number of portions of wholegrains consumed and whether a portion of nuts were consumed, reported daily via the PRO-Diary wrist device.	8-week intervention period
Primary	Change in plasma alkylresorcinol levels reflecting wholegrains intake	Concentration of alkylresorcinols as a measure of wholegrains intake in nmol/L	Every 4 weeks from start of study up to 24 weeks
Primary	Change in blood pressure	Blood pressure (both systolic and diastolic) will be taken daily by participants via the QardioArm wireless blood pressure monitor. 3 measurements are taken automatically and averaged.	From start of study up to 24 weeks
Secondary	Correlation between adherence and blood pressure change	Correlation between adherence and blood pressure change will be examined using N-of-1 dynamic modelling. Daily blood pressure measurements and PRO-Diary questionnaire responses will be provided during the whole study. Questionnaire responses will be given on a Visual Analogue Scale from 0-100.	8-week intervention period
Secondary	Total, LDL and HDL cholesterol levels	Fasted blood samples will be taken to determine whether wholegrains and nuts consumption has an effect on blood cholesterol levels.	4-week blood samples
Secondary	Amount of wholegrains and nuts consumed during follow-up reported using PRO-Diary questionnaires	For the final 8 weeks of the study, provision of wholegrains and nuts will cease but participants will continue to be asked about their consumption of these products through daily PRO-Diary questionnaires. This is to determine if habit formation has occurred and led to continuation of consumption of these products	8-week follow-up phase
Secondary	Determination of personal factors which correlate with study outcomes using Ecological Momentary Assessment (EMA) through the PRO-Diary device	Participants will respond to semi-personalised questionnaires daily using a Visual Analogue Scale from 0-100 using the PRO-Diary device. The PRO-Diary will also track movement collected during 60-second epochs via accelerometry. The influence of these factors on the primary and secondary outcomes above will be aggregated using N-of-1 dynamic modelling. Due to the semi-personalised nature of the questionnaires, the exact predictors examined in each N-of-1 study will differ. Analysis of each N-of-1 study will be conducted separately.	24 weeks